-
EP3685846
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3685846
| EP3685846 - USE OF THIOSTREPTON OR ITS DERIVATIVES FOR THE TREATMENT OF GENETIC DISEASES LINKED TO A PROTEIN CONFORMATIONAL DISORDER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 11.06.2021 Database last updated on 19.10.2024 | |
| Former | The application has been published Status updated on 26.06.2020 | Most recent event Tooltip | 11.06.2021 | Application deemed to be withdrawn | published on 14.07.2021 [2021/28] | Applicant(s) | For all designated states Genethon 1 bis rue de l'Internationale 91000 Evry / FR | For all designated states Centre d'Etude des Cellules Souches (CECS) 28 Rue Henri Desbruères 91100 Corbeil Essonnes / FR | For all designated states Institut National de la Santé et de la Recherche Médicale 101, rue de Tolbiac 75013 Paris / FR | For all designated states Universite d'Evry Val d'Essonne Boulevard Francois Mitterand 91025 Evry / FR | [2020/31] | Inventor(s) | 01 /
RICHARD, Isabelle 113 Chemin du CGB 91100 CORBEIL ESSONNES / FR | 02 /
NISSAN, Xavier 148 Rue de Paris 94220 CHARENTON-LE-PONT / FR | 03 /
HENRIQUES, Sara 5 Villa Edouard Vaillant 91000 EVRY / FR | 04 /
HOCH, Lucile 14 Rue Jean Jacques Rousseau 78180 MONTIGNY LE BRETONNEUX / FR | [2020/31] | Representative(s) | Cabinet Laurent & Charras Le Contemporain 50 Chemin de la Bruyère 69574 Dardilly Cedex / FR | [2020/31] | Application number, filing date | 19305097.8 | 24.01.2019 | [2020/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3685846 | Date: | 29.07.2020 | Language: | EN | [2020/31] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 16.05.2019 | Classification | IPC: | A61K38/12, A61K31/4709, A61P21/00, A61P17/06 | [2020/31] | CPC: |
A61K38/12 (EP);
A61K38/05 (EP);
A61P17/06 (EP);
A61P21/00 (EP)
| C-Set: |
A61K38/05, A61K2300/00 (EP);
A61K38/12, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/31] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | VERWENDUNG VON THIOSTREPTON ODER DESSEN DERIVATEN ZUR BEHANDLUNG VON GENETISCHEN ERKRANKUNGEN IM ZUSAMMENHANG MIT EINER PROTEINFEHLFALTUNGSERKRANKUNG | [2020/31] | English: | USE OF THIOSTREPTON OR ITS DERIVATIVES FOR THE TREATMENT OF GENETIC DISEASES LINKED TO A PROTEIN CONFORMATIONAL DISORDER | [2020/31] | French: | UTILISATION DE THIOSTREPTON OU DE SES DÉRIVÉS POUR LE TRAITEMENT DE MALADIES GÉNÉTIQUES LIÉES À UN TROUBLE CONFORMATIONNEL DE PROTÉINE | [2020/31] | Examination procedure | 30.01.2021 | Application deemed to be withdrawn, date of legal effect [2021/28] | 22.02.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2021/28] | Fees paid | Renewal fee | 26.01.2021 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2008095112 (UNIV ILLINOIS [US], et al) [I] 1-12 *cf. abstract, examples 4 and 5 at pages 30 and 31ff., claims 5-9*; | [I]WO2009115287 (UNIV DORTMUND TECH [DE], et al) [I] 1-12*cf. abstract, page 39, 3rd para., claims 1, 17 and 18*; | [I] - SAYANJALI BEHNAM ET AL, "Propionibacterium acnesinhibits FOXM1 and induces cell cycle alterations in human primary prostate cells", INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, URBAN UND FISCHER, DE, (20160628), vol. 306, no. 7, doi:10.1016/J.IJMM.2016.06.006, ISSN 1438-4221, pages 517 - 528, XP029784999 [I] 1-12 *cf. abstract and last para. of the right-hand col. at page 526* DOI: http://dx.doi.org/10.1016/j.ijmm.2016.06.006 | by applicant | WO2008009802 | WO2010106295 | WO2013072587 | WO2014013184 | - BARTOLI, M. et al., Human molecular genetics, (20080000), vol. 17, pages 1214 - 1221 | - GASTALDELLO, S. et al., The American journal of pathology, (20080000), vol. 173, pages 170 - 181 | - KELLY; PAN, J. Am. Chem. Soc., (20090000), vol. 131, no. 12, pages 4327 - 34 | - NICOLAOU, Angew Chem Int Ed Engl., (20120000), vol. 51, no. 50, pages 12414 - 36 | - SANDU et al., J. Cell. Mol. Med., (20150000), vol. 19, no. 9, pages 2181 - 92 | - SANDU et al., Therefore, the present application proposes to use inhibitors of the 19S proteasome in that context | - KEY; MILLER, J. Am. Chem. Soc., (20170000), vol. 139, pages 15460 - 66 | - WANG; GARTEL, Mol. Cancer Ther., (20110000), vol. 10, no. 12, pages 2287 - 97 | - CHAOUCH, S., Human gene therapy, (20090000), vol. 20, pages 784 - 790 | - TAKAHASHI, K.; YAMANAKA, S., Cell, (20060000), vol. 126, pages 663 - 676 |